Category: Pharma, Life Sciences & Med Tech Players
-
CureVac sues Moderna in Delaware over Spikevax patents, seeking treble damages but no injunction
CureVac sues Moderna for treble damages but not an injunction over 10 patents related to Spikevax. The case adds to broader post-COVID mRNA patent battles.
-
Human lives at stake: Munich court warns against chilling effect of excessive prior art eligibility as rivaroxaban dispute heads into final round
All other Munich landmark rulings related to access to injunctive relief, be it about SEPs, the invalidity defense to PIs, or anti-antisuit relief in different forms. The latest one is about patients more so than patents.
-
Federal Circuit revives Teva’s $177M (potentially $530M) damages verdict against Eli Lilly over Emgality headache drug
A $177M jury verdict, potentially tripled for willfulness, has been reinstated, and the standards for written description and enablement for genus-related patents have been clarified.
-
São Paulo court grants Johnson & Johnson extraordinary emergency relief and reinstates injunction in med tech patent dispute
The President of the Private Law Section of the São Paulo Court of Justice granted extraordinary emergency relief, reinstating an injunction previously lifted on appeal in this med tech patent dispute, in a procedurally unusual intervention.
-
Another semaglutide generic enters India as Novo Nordisk patent expires, no injunction issues
The Delhi High Court has issued a ruling allowing a generic version of semaglutide to be sold without an injunction and indicating a cautious approach to late-stage enforcement, favoring restricted entry over exclusion, by basing it around a contested claim limitation.
-
Colombia pushes for compulsory licensing of U.S. pharma company’s patents
Colombia’s Health Minister has revived a previous administration’s investigation into four of U.S. pharma company Gilead’s patents at the core of Hepatitis-C treatment, issuing a public interest declaration to make the licensing of such patents compulsory.
-
Novo Nordisk settles U.S. semaglutide patent infringement dispute, but denied Indian interim injunction again
While Novo Nordisk has struck an agreement with U.S. telehealth platform Hims & Hers to sell Ozempic and Wegovy, the Delhi High Court has once again denied its request for an interim injunction against Dr. Reddy’s Laboratories to block its sales of semaglutide products after its patent expires in 10 days.
-
An interview with bioMérieux IP head Dr. James Robertson
James Robertson, the in vitro diagnostics company’s global head of IP, talked to ip fray about its activities in the Unified Patent Court and some of the successes and hurdles he has experienced since moving from pharma into diagnostics IP management.
-
Moderna, Genevant, Arbutus settle global mRNA patent infringement dispute
Moderna could have to pay up to $2.25 billion as part of the settlement agreement, but remains confident it will close 2026 with up to $5 billion in cash and cash equivalents as a result of the deal.
-
Novo Nordisk targets Canadian pharma giant Apotex in new oral semaglutide patent infringement suit
Novo Nordisk has sued Canada’s Apotex in the United States District Court for the District of New Jersey over the alleged infringement of six patents related to its oral weightloss drug Rybelsus.